QualityStocksNewsBreaks – Moleculin Biotech Inc. (NASDAQ: MBRX) Secures $78M in Underwritten Public Offering
Moleculin Biotech (NASDAQ: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors…